ASX:EX1 Exopharm (EX1) Stock Price, News & Analysis → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Free EX1 Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Exopharm alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About ExopharmExopharm Limited develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia. The company's technology includes LOAD technology platform that enables loading of active pharmaceutical ingredient (API) into exosomes; Ligand-based Exosome Affinity Purification (LEAP) technology that solves the critical bottleneck of exosome isolation and purification; MASTER CELL BANK to manufacture clinical-grade engineered exosomes; EVPS technology platform that allows specific molecules to be attached to the surface of exosomes to target them to selected tissues, organs, or cell types; EXORIA, a novel and proprietary dye that tags invisible exosomes to enhance tracking in experimental studies and laboratory analysis; and FORMULATION H to enable the stable storage and transport of exosome medicines. Exopharm Limited has research collaboration agreements with Astellas Institute for Regenerative Medicine. The company was incorporated in 2013 and is based in Camberwell, Australia.Read More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. EX1 Stock News HeadlinesMay 1, 2024 | finanznachrichten.deTryp Therapeutics and Exopharm Limited Announce Completion of Plan of ArrangementNovember 20, 2023 | bbc.comEX1 - Weather warnings issuedMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...November 18, 2023 | finance.yahoo.comExopharm Limited (EX1.XA)August 30, 2023 | finance.yahoo.comExopharm Full Year 2023 Earnings: AU$0.036 loss per share (vs AU$0.064 loss in FY 2022)May 22, 2023 | finance.yahoo.comOne Exopharm Insider Raised Their Stake In The Previous YearDecember 2, 2022 | finance.yahoo.comExopharm Limited (ASX:EX1) insider upped their holding by 15% earlier this yearAugust 27, 2022 | finance.yahoo.comExopharm Limited (EX1.AX)May 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...June 22, 2022 | finance.yahoo.comExopharm Limited (ASX:EX1) up 14%, but insiders are still down 49% after purchasing AU$895k of stock last yearMay 11, 2022 | finance.yahoo.comIs Exopharm (ASX:EX1) In A Good Position To Deliver On Growth Plans?See More Headlines Receive EX1 Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exopharm and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:EX1 CUSIPN/A CIKN/A Webwww.exopharm.com Phone61 3 9111 0026FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,320,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-121.54% Return on Assets-51.37% Debt Debt-to-Equity Ratio37.16 Current Ratio7.82 Quick Ratio2.03 Sales & Book Value Annual Sales$1.18 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.39 Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares439,420,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.26 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Ian E. Dixon M.A.I.C.D.M.B.A., MBA, Ph.D., Founder, Technology Co-Founder, CEO MD & DirectorDr. Gregor Lichtfuss M.Sc.Co-Founder & Business Services ManagerMr. Johannes MuhlSenior Vice President of FinanceMr. David James Franks BEc (Age 54)C.A., F Fin, J.P., Company Secretary Key Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersClarke BarlowSold 10,000,000 sharesTotal: $110,000.00 ($0.01/share) This page (ASX:EX1) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exopharm Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
